Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 4/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265933 | 0.84 | ALDH1A1 (0.35) | PIM1PIM2PIM3ALDH1A1MEN1 | |
| SCHEMBL3661285 | 0.84 | CDK2 (0.38) | CDK2ALDH1A1KDM4EMEN1CYP1A2 | |
| SCHEMBL3272808 | 0.83 | IDH1 (0.35) | CDK2ALDH1A1KDM4EMEN1CYP1A2 | |
| SCHEMBL31080635 | 0.82 | CDK2 (0.36) | CDK2 | |
| SCHEMBL25259907 | 0.79 | CDK2 (0.40) | CDK2ALDH1A1KDM4EMEN1CYP1A2 | |
| SCHEMBL20780129 | 0.78 | MCHR1 (0.35) | CDK2 | |
| SCHEMBL3268357 | 0.77 | NUDT1 (0.43) | CDK2ALDH1A1HTR2AHTR2C | |
| SCHEMBL31080147 | 0.77 | NUDT1 (0.43) | CDK2ALDH1A1HTR2AHTR2C | |
| SCHEMBL15854715 | 0.77 | MAPT (0.36) | PIM1PIM2PIM3ALDH1A1MEN1 | |
| SCHEMBL29086453 | 0.76 | CDK2 (0.38) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-06-12 | — | — | US | disclosed |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-02-27 | — | — | US | disclosed |
| EP-4490150-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-01-15 | — | — | EP | disclosed |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4452965-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-10-30 | — | — | EP | disclosed |
| EP-3679032-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3679032-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023170025-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-09-14 | — | — | WO | disclosed |
| EP-4232425-A1 | CTPS1 INHIBITORS AND USES THEREOF | Nimbus Clotho, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011025690-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
| CN-101679266-A | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR5 | CDK2 2299/4885PIM1 3500/4885PIM2 3744/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CDK2 187/4885PIM1 1/4885PIM2 2/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CDK2 3294/4885PIM1 2865/4885PIM2 2671/4885 |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | CDK2 954/4885PIM1 2829/4885PIM2 3491/4885 |
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | CDK2 2055/4885PIM1 2598/4885PIM2 3444/4885 |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | CTPS1, CTPS2, ECHS1 | CDK2 1637/4885PIM1 2993/4885PIM2 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.